Compare BioNano Genomics Inc (BNGO) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Cognizant Technology Solutions Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Cognizant Technology Solutions Corp trades at $58 (market cap $26.40B). The key difference: Cognizant Technology Solutions Corp is far larger — about 1932.7× BioNano Genomics Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CTSH | |
|---|---|---|
Market Cap | $13.66M | $26.40B |
Sector | Health | Technology |
52-Week High | $4.92 | $86.70 |
52-Week Low | $1.06 | $38.73 |
Enterprise Value | $16.26M | $27.44B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Cognizant (CTSH) trades at $58.19, down 0.21% today, with a bullish technical signal and strong cash flow. Recent Q2 2026 earnings missed estimates at $1.37 EPS, but revenue beat. The company maintains a solid net income margin of 10.26% and trades at a P/E of 12.58, below industry averages. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience amid AI-driven strategic shifts.
Outlook remains cautiously optimistic with upside potential from AI initiatives and financial services growth, though risks include client spending caution and competitive pressures. The stock's current valuation offers a margin of safety, but investors should monitor execution on AI integration and macroeconomic headwinds affecting IT spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
